NCT02265510 is a Phase 1, PHASE2 clinical trial of INCB052793 in Solid Tumors, sponsored by Incyte Corporation.

Who is sponsoring NCT02265510?

NCT02265510 is sponsored by Incyte Corporation.

What drugs are being tested in NCT02265510?

Interventions in NCT02265510: INCB052793, gemcitabine, nab-paclitaxel, dexamethasone, Carfilzomib, bortezomib, lenalidomide, azacitidine, INCB052793, pomalidomide, INCB050465, INCB039110.

What condition does NCT02265510 study?

NCT02265510 studies Solid Tumors, Advanced Malignancies, Metastatic Cancer.

Is NCT02265510 still recruiting?

NCT02265510 is currently terminated. Last updated 17 April 2020.

Are results published for NCT02265510?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-04-17 · How we verify

NCT02265510

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Terminated Phase 1, PHASE2 Results posted Last updated 17 April 2020

What this trial tests

Phase 1, PHASE2 trial testing INCB052793 in Solid Tumors in 83 participants. Terminated before completion.

Timeline

10 September 2014

Primary endpoint
27 February 2019

27 February 2019

Quick facts

Lead sponsor	Incyte Corporation
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	83
Start date	10 September 2014
Primary completion	27 February 2019
Estimated completion	27 February 2019
Sites	14 locations across United States

Drugs / interventions tested

INCB052793
gemcitabine
nab-paclitaxel
dexamethasone (dexamethasone) — full drug profile →
Carfilzomib (carfilzomib) — full drug profile →
bortezomib (bortezomib) — full drug profile →
lenalidomide — full drug profile →
azacitidine (azacitidine) — full drug profile →
INCB052793
pomalidomide
INCB050465
INCB039110

Conditions studied

Solid Tumors — all drugs for Solid Tumors →
Advanced Malignancies — all drugs for Advanced Malignancies →
Metastatic Cancer — all drugs for Metastatic Cancer →

Sponsor

Incyte Corporation — full company profile →

Who can join

18 and older, any sex, with Solid Tumors or Advanced Malignancies. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Phase 1a and 1b: Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) and Serious Adverse Event (SAE) Primary · From first dose of study drug up to 30 days after last dose of study drug (Up to approximately 3.4 years)

An AE is any untoward medical occurrence in a subject administered a medicinal investigational drug. The untoward medical occurrence does not necessarily have to have a causal relationship with treatment. An SAE is any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalization or prolongation of present hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect or is a medically important event that may not be immediately life-threatening or result in death or hospitalization. A TEAE was defi

TEAE

Group	Value	95% CI
Phase 1a TGA - INCB052793 15 mg	3
Phase 1a TGA - INCB052793 25 mg	3
Phase 1a TGA - INCB052793 35 mg	6
Phase 1a TGA - INCB052793 50 mg	4
Phase 1a TGA - INCB052793 75 mg	3
Phase 1a TGA - INCB052793 100 mg	6
Phase 1a TGB - INCB052793 25 mg	3
Phase 1a TGB - INCB052793 35 mg	4
Phase 1a TGB - INCB052793 50 mg	4
Phase 1b Cohort B - INCB052793 25 mg + Dexamethasone 40 mg	7
Phase 1b Cohort F - INCB052793 25 mg + Azacytidine 75 mg/m^2	5
Phase 1b Cohort F - INCB052793 35 mg + Azacytidine 75 mg/m^2	16

SAE

Group	Value	95% CI
Phase 1a TGA - INCB052793 15 mg	0
Phase 1a TGA - INCB052793 25 mg	1
Phase 1a TGA - INCB052793 35 mg	0
Phase 1a TGA - INCB052793 50 mg	2
Phase 1a TGA - INCB052793 75 mg	3
Phase 1a TGA - INCB052793 100 mg	2
Phase 1a TGB - INCB052793 25 mg	1
Phase 1a TGB - INCB052793 35 mg	2
Phase 1a TGB - INCB052793 50 mg	2
Phase 1b Cohort B - INCB052793 25 mg + Dexamethasone 40 mg	5
Phase 1b Cohort F - INCB052793 25 mg + Azacytidine 75 mg/m^2	4
Phase 1b Cohort F - INCB052793 35 mg + Azacytidine 75 mg/m^2	14

Phase 2: Objective Response Rate (ORR) in Hematological Malignancies Primary · Baseline through end of study (Up to approximately 4.5 years)

ORR is defined as the proportion of participants who achieved complete response (CR), CR with incomplete hematologic recovery (CRi), partial response (PR), or hematologic improvement (HI), using the IWG response criteria.

Group	Value	95% CI
Phase 2 Cohort I-INCB052793 +Azacytidine (AML)	0
Phase 2 Cohort I-INCB052793 +Azacytidine (MDS)	1
Phase 2 Cohort J-Itacitinib +Azacitidine (AML)	1
Phase 2 Cohort J-Itacitinib +Azacitidine (MDS)	0

Phase 1A and 1B: Percentage of Participants With Response as Determined by Investigator's Assessment Secondary · Baseline through end of study (Up to approximately 4.5 years)

Response rate is defined as the percentage of participants who achieved best overall response (BOR) as determined by IWG response criteria of investigator's assessment. A participant was considered an objective responder based on the following- Solid tumors: participant had a best overall response (BOR) of CR or PR, Lymphoma: participant had a BOR of complete radiologic response/complete metabolic response or partial remission/partial metabolic response, AML: participant had a BOR of CR, CRi, morphological leukemia-free state (MLFS), or PR, MDS: participant had a BOR of CR, PR, or marrow CR, M

Group	Value	95% CI
Phase 1a TGA - INCB052793 in Solid Tumors	0
Phase 1a TGB - INCB052793 in Lymphoma	0
Phase 1a TGB - INCB052793 in MDS/MPN	1
Phase 1a TGB - INCB052793 in MM	0
Phase 1b Cohort B - INCB052793 + Dexamethasone in MM	2
Phase 1b Cohort F-INCB052793 +Azacytidine in AML	4
Phase 1b Cohort F-INCB052793 +Azacytidine in MDS	3
Phase 1b Cohort F-INCB052793 +Azacytidine in MDS/MPN	2

Phase 2: Number of Participants With at Least One TEAE and SAE Secondary · From first dose of study drug up to 30 days after last dose of study drug (Up to approximately 1.3 years)

TEAE

Group	Value	95% CI
Phase 2 Cohort I - INCB052793 35 mg + Azacytidine 75 mg/m^2	9
Phase 2 Cohort J - Itacitinib 300 mg + Azacitidine 75 mg/m^2	10

SAE

Group	Value	95% CI
Phase 2 Cohort I - INCB052793 35 mg + Azacytidine 75 mg/m^2	7
Phase 2 Cohort J - Itacitinib 300 mg + Azacitidine 75 mg/m^2	8

Phase 1a, 1b, and Phase 2: Cmax: Maximum Observed Plasma Concentration for INCB052793 Secondary · Cycle 1, Day 15: predose and 0.5, 1, 2, 4, 6 hours postdose in Phase 1a; 0 (predose), 0.08, 0.5, 1, 2, 4, 6 and 8 hours postdose in Phase 1b and Phase 2

Cmax is defined as the maximum observed plasma concentration measured at steady state (Day 15). For PK analyses subjects in TGA and TGB are combined by dosage group because only 3 subjects were enrolled in each dose group in TGB and 4 subject for first dose in TGB 50 mg.

Group	Value	95% CI
Phase 1a TGA - INCB052793 15 mg	522	± 126
Phase 1a TGA - INCB052793 25 mg	1110	± 324
Phase 1a TGA - INCB052793 35 mg	1120	± 543
Phase 1a TGA - INCB052793 50 mg	2050	± 1070
Phase 1a TGA - INCB052793 75 mg	1840	± 563
Phase 1a TGA - INCB052793 100 mg	2890	± 1690
Phase 1b Cohort B - INCB052793 25 mg + Dexamethasone 40 mg	928	± 263
Phase 1b Cohort F - INCB052793 25 mg + Azacytidine 75 mg/m^2	1270	± 856
Phase 1b Cohort F - INCB052793 35 mg + Azacytidine 75 mg/m^2	1480	± 588
Phase 2 Cohort I - INCB052793 35 mg + Azacytidine 75 mg/m^2	1610	± 745

Phase 1a, 1b, and Phase 2: Tmax: Time to Maximum Plasma Concentration for INCB052793 Secondary · Cycle 1, Day 15: predose and 0.5, 1, 2, 4, 6 hours postdose in Phase 1a; 0 (predose), 0.08, 0.5, 1, 2, 4, 6 and 8 hours postdose in Phase 1b and Phase 2

Tmax is the time to maximum (peak) observed plasma drug concentration. Summary of Steady-State, Day 15, was evaluated by dosing regimen. For PK analyses subjects in TGA and TGB are combined by dosage group because only 3 subjects were enrolled in each dose group in TGB and 4 subject for first dose in TGB 50 mg.

Group	Value	95% CI
Phase 1a TGA - INCB052793 15 mg	1.1	0.48 – 2.0
Phase 1a TGA - INCB052793 25 mg	0.76	0.47 – 2.0
Phase 1a TGA - INCB052793 35 mg	2.0	0.50 – 4.0
Phase 1a TGA - INCB052793 50 mg	1.1	1.0 – 2.1
Phase 1a TGA - INCB052793 75 mg	2.2	1.1 – 4.0
Phase 1a TGA - INCB052793 100 mg	2.0	0.43 – 2.1
Phase 1b Cohort B - INCB052793 25 mg + Dexamethasone 40 mg	1.0	0.43 – 2.0
Phase 1b Cohort F - INCB052793 25 mg + Azacytidine 75 mg/m^2	1.1	0.58 – 7.7
Phase 1b Cohort F - INCB052793 35 mg + Azacytidine 75 mg/m^2	1.1	0.47 – 2.1
Phase 2 Cohort I - INCB052793 35 mg + Azacytidine 75 mg/m^2	0.51	0.33 – 2.1

Phase 1a, 1b, and Phase 2: AUC0-τ: Area Under the Plasma Concentration-time Curve Over Dosing Interval for INCB052793 Secondary · Cycle 1, Day 15: predose and 0.5, 1, 2, 4, 6 hours postdose in Phase 1a; 0 (predose), 0.08, 0.5, 1, 2, 4, 6 and 8 hours postdose in Phase 1b and Phase 2

AUC0-τ is the area under the plasma concentration-time curve from time = 0 to the last measurable concentration at time = t measured at steady state (Day 15). For PK analyses subjects in TGA and TGB are combined by dosage group because only 3 subjects were enrolled in each dose group in TGB and 4 subject for first dose in TGB 50 mg.

Group	Value	95% CI
Phase 1a TGA - INCB052793 15 mg	4750	± 1380
Phase 1a TGA - INCB052793 25 mg	9170	± 4290
Phase 1a TGA - INCB052793 35 mg	8430	± 2520
Phase 1a TGA - INCB052793 50 mg	14700	± 6670
Phase 1a TGA - INCB052793 75 mg	18300	± 10600
Phase 1a TGA - INCB052793 100 mg	27800	± 12300
Phase 1b Cohort B - INCB052793 25 mg + Dexamethasone 40 mg	6390	± 1690
Phase 1b Cohort F - INCB052793 25 mg + Azacytidine 75 mg/m^2	9580	± 6710
Phase 1b Cohort F - INCB052793 35 mg + Azacytidine 75 mg/m^2	10200	± 5260
Phase 2 Cohort I - INCB052793 35 mg + Azacytidine 75 mg/m^2	9380	± 4390

Phase 1a, 1b, and Phase 2: Cmax: Maximum Observed Plasma Concentration of Itacitinib Secondary · Cycle 1, Day 15: predose and 0.5, 1, 2, 4, 6 hours postdose in Phase 1a; 0 (predose), 0.08, 0.5, 1, 2, 4, 6 and 8 hours postdose in Phase 1b and Phase 2

Cmax is defined as the maximum observed plasma concentration measured at steady state (Day 15).

Group	Value	95% CI
Phase 2 Cohort J - Itacitinib 300 mg + Azacitidine 75 mg/m^2	1310	± 638

Phase 1a, 1b, and Phase 2: Tmax: Time to Maximum Plasma Concentration for Itacitinib Secondary · Cycle 1, Day 15: predose and 0.5, 1, 2, 4, 6 hours postdose in Phase 1a; 0 (predose), 0.08, 0.5, 1, 2, 4, 6 and 8 hours postdose in Phase 1b and Phase 2

Tmax is the time to maximum (peak) observed plasma drug concentration.

Group	Value	95% CI
Phase 2 Cohort J - Itacitinib 300 mg + Azacitidine 75 mg/m^2	3.5	1.0 – 8.0

Phase 1a, 1b, and Phase 2: AUC0-τ: Area Under the Plasma Concentration-time Curve Over Dosing Interval for Itacitinib Secondary · Cycle 1, Day 15: predose and 0.5, 1, 2, 4, 6 hours postdose in Phase 1a; 0 (predose), 0.08, 0.5, 1, 2, 4, 6 and 8 hours postdose in Phase 1b and Phase 2

AUC0-τ is the area under the plasma concentration-time curve from time = 0 to the last measurable concentration at time = t measured at steady state (Day 15).

Group	Value	95% CI
Phase 2 Cohort J - Itacitinib 300 mg + Azacitidine 75 mg/m^2	9870	± 7350

Adverse events — posted to ClinicalTrials.gov

Time frame: From first dose of study drug up to 30-35 days after last dose of study drug (Up to approximately 3.4 years). Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Phase 1a TGA - INCB052793 15 mg

Serious: 0/3 (0%)

Deaths: 2/3

Phase 1a TGA - INCB052793 25 mg

Serious: 1/3 (33%)

Deaths: 0/3

Phase 1a TGA - INCB052793 35 mg

Serious: 0/6 (0%)

Deaths: 2/6

Phase 1a TGA - INCB052793 50 mg

Serious: 2/4 (50%)

Deaths: 2/4

Phase 1a TGA - INCB052793 75 mg

Serious: 3/3 (100%)

Deaths: 1/3

Phase 1a TGA - INCB052793 100 mg

Serious: 2/6 (33%)

Deaths: 3/6

Phase 1a TGB - INCB052793 25 mg

Serious: 1/3 (33%)

Deaths: 2/3

Phase 1a TGB - INCB052793 35 mg

Serious: 2/4 (50%)

Deaths: 1/4

Phase 1a TGB - INCB052793 50 mg

Serious: 2/4 (50%)

Deaths: 3/4

Phase 1b Cohort B - INCB052793 25 mg + Dexamethasone 40 mg

Serious: 5/7 (71%)

Deaths: 3/7

Phase 1b Cohort F - INCB052793 25 mg + Azacytidine 75 mg/m^2

Serious: 4/5 (80%)

Deaths: 4/5

Phase 1b Cohort F - INCB052793 35 mg + Azacytidine 75 mg/m^2

Serious: 14/16 (88%)

Deaths: 12/16

Phase 2 Cohort I - INCB052793 35 mg + Azacytidine 75 mg/m^2

Serious: 7/9 (78%)

Deaths: 7/9

Phase 2 Cohort J - Itacitinib 300 mg + Azacitidine 75 mg/m^2

Serious: 8/10 (80%)

Deaths: 6/10

Serious adverse events (63 terms)

Reaction	System	Phase 1a TGA - INCB052793 …	Phase 1a TGA - INCB052793 …	Phase 1a TGA - INCB052793 …	Phase 1a TGA - INCB052793 …	Phase 1a TGA - INCB052793 …	Phase 1a TGA - INCB052793 …	Phase 1a TGB - INCB052793 …	Phase 1a TGB - INCB052793 …	Phase 1a TGB - INCB052793 …	Phase 1b Cohort B - INCB05…	Phase 1b Cohort F - INCB05…	Phase 1b Cohort F - INCB05…	Phase 2 Cohort I - INCB052…	Phase 2 Cohort J - Itaciti…
Febrile neutropenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pneumonia	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Sepsis	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pulmonary embolism	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Gastrointestinal haemorrhage	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Intestinal obstruction	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Small intestinal obstruction	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Staphylococcal bacteraemia	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Platelet count decreased	Investigations	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Dehydration	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pancreatic carcinoma metastatic	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Haemoptysis	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Respiratory failure	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Embolism	Vascular disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Lymphadenopathy	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Urinary tract obstruction	Renal and urinary disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Herpes zoster	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pharyngitis streptococcal	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Hypercalcaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Encephalopathy	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Spinal cord compression	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—

Other adverse events (308 terms — click to expand)

Reaction	System	Phase 1a TGA - INCB052793 …	Phase 1a TGA - INCB052793 …	Phase 1a TGA - INCB052793 …	Phase 1a TGA - INCB052793 …	Phase 1a TGA - INCB052793 …	Phase 1a TGA - INCB052793 …	Phase 1a TGB - INCB052793 …	Phase 1a TGB - INCB052793 …	Phase 1a TGB - INCB052793 …	Phase 1b Cohort B - INCB05…	Phase 1b Cohort F - INCB05…	Phase 1b Cohort F - INCB05…	Phase 2 Cohort I - INCB052…	Phase 2 Cohort J - Itaciti…
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Thrombocytopenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Alanine aminotransferase increased	Investigations	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Stomatitis	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Injection site reaction	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Aspartate aminotransferase increased	Investigations	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Hypertriglyceridaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Rash maculo-papular	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Neutropenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Platelet count decreased	Investigations	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Hyperglycaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Oropharyngeal pain	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Chills	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Oedema peripheral	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Blood alkaline phosphatase increased	Investigations	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Blood cholesterol increased	Investigations	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Neutrophil count decreased	Investigations	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Hypophosphataemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Muscular weakness	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Myalgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Haematuria	Renal and urinary disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Epistaxis	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Hypertension	Vascular disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Leukopenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Aphthous stomatitis	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Gastrooesophageal reflux disease	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Oral pain	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Injection site bruising	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—

Most-reported serious reactions: Febrile neutropenia, Pyrexia, Pneumonia, Sepsis, Pulmonary embolism, Gastrointestinal haemorrhage, Intestinal obstruction, Nausea.

Data from ClinicalTrials.gov NCT02265510 adverse events section.

Sponsor's own description

This was a study of INCB052793 given to patients with advanced malignancies that was to be conducted in three phases; Phase 1a (Monotherapy) and Phase 1b (Combination Therapy) and Phase 2 (Combination therapy of INCB052793 with azacitidine and itacitinib with azacitidine). Phase 1 had two parts; a dose escalation (Part 1) and an expansion (Part 2).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting PI3K in cancer: mechanisms and advances in clinical trials.
Yang J, Nie J, Ma X, Wei Y, et al · · 2019 · cited 1142× · PMID 30782187 · DOI 10.1186/s12943-019-0954-x
Targeting Inflammation in Cancer Prevention and Therapy.
Todoric J, Antonucci L, Karin M. · · 2016 · cited 278× · PMID 27913448 · DOI 10.1158/1940-6207.capr-16-0209
Signal Transducer and Activator of Transcription (STATs) Proteins in Cancer and Inflammation: Functions and Therapeutic Implication.
Loh CY, Arya A, Naema AF, Wong WF, et al · · 2019 · cited 241× · PMID 30847297 · DOI 10.3389/fonc.2019.00048
CSF1R<sup>+</sup> Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype.
Candido JB, Morton JP, Bailey P, Campbell AD, et al · · 2018 · cited 182× · PMID 29719257 · DOI 10.1016/j.celrep.2018.03.131
The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia.
Schroeder MA, Choi J, Staser K, DiPersio JF. · · 2018 · cited 82× · PMID 29289756 · DOI 10.1016/j.bbmt.2017.12.797
The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.
Tundo GR, Sbardella D, Santoro AM, Coletta A, et al · · 2020 · cited 78× · PMID 32442437 · DOI 10.1016/j.pharmthera.2020.107579
Targeting the JAK/STAT pathway in solid tumors.
Qureshy Z, Johnson DE, Grandis JR. · · 2020 · cited 76× · PMID 33521321 · DOI 10.20517/2394-4722.2020.58
Targeting STAT3 with Proteolysis Targeting Chimeras and Next-Generation Antisense Oligonucleotides.
Shiah JV, Grandis JR, Johnson DE. · · 2021 · cited 22× · PMID 33203730 · DOI 10.1158/1535-7163.mct-20-0599

Verify or expand the search:

Other trials of INCB052793

Trials testing the same drug.

NCT03906344 — Expanded Access Use of INCB052793 to Treat a Single Patient With Myelofibrosis · no longer available

Other recruiting trials for Solid Tumors

Currently open trials in the same condition.

NCT07529002 — Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors · recruiting
NCT07416123 — A Study of GEN1106 in Participants With Solid Tumors · Phase 1 · recruiting
NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
NCT07395258 — A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Differe · Phase 1 · recruiting
NCT07505069 — Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors · EARLY_PHASE1 · recruiting

Other Incyte Corporation trials

Trials by the same sponsor.

NCT07124078 — A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Di · Phase 2 · recruiting
NCT07441694 — Study of INCA036978 in Participants With Myeloproliferative Neoplasms · Phase 1 · recruiting
NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting
NCT07284849 — A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 i · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02265510 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Incyte Corporation
Last refreshed: 17 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02265510.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT02265510

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (63 terms)

Sponsor's own description

Publications & conference data

Related trials

Other trials of INCB052793

Other recruiting trials for Solid Tumors

Other Incyte Corporation trials

Verify against primary sources